acute ischemic stroke
Conditions
Interventions
Reperfusion therapy+Sublingual Edaravone Dexborneol group :Sublingual Edaravone Dexborneol tablets (1 tablet bid 14 days)
Reperfusion therapy+placebo group:placebo (1 tablet bid 14 days)
Sponsors
Zigong Fourth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years old; 2. Modified Rankin Scale (mRS) score <=1 before the onset of this illness; 3. NIHSS <=25; 4. Time since onset <=4.5 hours and meets the criteria for intravenous thrombolysis; 5. Informed consent signed by family members.
Exclusion criteria
Exclusion criteria: 1. Has already used neuroprotective drugs after onset of illness; 2. Has contraindications to intravenous thrombolysis; 3. Patients who cannot cooperate with the use of edaravone dexborneol sublingual tablets for various reasons; 4. Patients with severe heart, liver, or kidney dysfunction; 5. Patients with diseases such as end-stage cancer or end-stage heart disease that interfere with clinical evaluation; 6. Pregnant or breastfeeding patients; 7. Patients who withdraw from the study midway; 8. Participants in other clinical studies; 9. Other situations deemed inappropriate for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with mRS score <=1 at 90 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with mRS score <=2 at 90 days;Modified Rankin Scale (mRS) score on day 90 after randomization;change in NIHSS score from baseline to day 14;the proportion of patients with an NIHSS score of 1or less on day14, 30, and 90 after randomization; | — |
Countries
China
Contacts
Public ContactYunbo Chen
Zigong Fourth People's Hospital
Outcome results
None listed